JPRN-UMIN000042482Recruiting未知
Effect of Semaglutide 0.25mg on glycemic controls in type2 diabetes patients compared with dulaglutide 0.75mg. - Effect of Semaglutide 0.25mg on glycemic controls in type2 diabetes patients compared with dulaglutide 0.75mg.
Saiseikai Yokohamashi Nanbu Hospital0 sites20 target enrollmentStarted: November 18, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Pationts received insulin 2) Patients with severe liver dysfunction 3) Patients with severe renal dysfunction(eGFR<30ml/min/1.73) 4) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0 5) Patients taking steroid 6) Patients with malignant tumor currently undergoing treatment 7) Pregnant or lactating woman 8) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Investigators
Similar Trials
Recruiting
Not Applicable
Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patientstype 2 diabetesJPRN-jRCT1031210620Ohara Makoto58
Completed
Not Applicable
Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patientsType 2 diabetes mellitusJPRN-UMIN000046938Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine60
Completed
Not Applicable
Effect of semaglutide on glucose variability and oxidative stress in type 2 diabetes patientsJPRN-UMIN000042670Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine42
Active, not recruiting
Phase 3
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS)CTRI/2019/06/019817ovo Nordisk AS
Active, not recruiting
Phase 1
Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetesHeart failure with preserved ejection fractionDiabetes Mellitus, type 2MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849EUCTR2020-004170-22-ATovo Nordisk A/S610